Gain Therapeutics financials
$1.68−5.08%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $55.2K | $132.6K | $165.0K |
| Gross profit | $0.00 | $0.00 | $55.2K | $132.6K | $165.0K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | -$13.9M |
| Net margin | — | — | −40354.3% | −13262.0% | −8418.9% |
| Diluted EPS | $-0.61 | $-0.89 | $-1.71 | $-1.48 | $-1.37 |
| EBITDA | -$18.6M | -$20.3M | -$22.2M | -$17.7M | -$13.8M |
| Operating cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M |
| Free cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.8M | -$12.5M |
| Diluted shares | 33.0M | 22.9M | 13.0M | 11.9M | 10.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $20.8M | $10.4M | $11.8M | $7.3M | $36.9M |
| Short-term investments | $0.00 | $0.00 | $5.0M | $12.8M | $0.00 |
| Total debt | $401.0K | $438.5K | $567.9K | $603.4K | $694.3K |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M |
| Shareholders' equity | $18.6M | $7.3M | $12.6M | $18.9M | $34.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology